Research Activity – Page 39

Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications

10 months ago talkbio0Tagged ARAMIS, ARASENS, Bayer, Clinical Trials, Corporation, darolutamide, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, non-metastatic castration-resistant prostate cancer, Nubeqa, Orion

NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation

Lexeo Therapeutics Reports Promising Early Data for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy

10 months ago talkbio0Tagged Ataxia, Cardiomyopathies, Clinical Trials, gene therapy, Hereditary Diseases, Infrequent, Lexeo, LX2006

Lexeo Therapeutics, LX2006, Gene Therapy, Friedreich Ataxia, Cardiomyopathy, Clinical Trials, Rare Genetic Disorders

Pfizer Advances Development of Once-Daily Oral GLP-1 Receptor Agonist Danuglipron for Obesity Treatment

10 months ago talkbio0Tagged Clinical Trials, Danuglipron, Drug Formulation Process, Glucagon-Like Peptide-1 Receptor, Obesity, once-daily, Pfizer, Weight Loss Medication

Pfizer, Danuglipron, GLP-1 Receptor Agonist, Obesity Treatment, Once-Daily Formulation, Clinical Trials, Weight Loss Medication

Pfizer’s R&D Chief Mikael Dolsten to Step Down After 15 Years of Leadership

10 months ago talkbio0Tagged COVID19 (disease), development aspects, Mikael, Pfizer, research, Scientific Officer, Successor Search, Vaccines

Pfizer, Mikael Dolsten, Chief Scientific Officer, Research and Development, COVID-19 Vaccine, Successor Search

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data

10 months ago talkbio0Tagged AMT-130, Clinical Trials, Composite, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, NEFL gene, Neurodegenerative Disorders, NfL, Phase, RMAT, Unified - Type of Agreement, UniQure, United States Food and Drug Administration

UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).

Cartesian Therapeutics Announces Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis Treatment

10 months ago talkbio0Tagged Autoimmune, Autoimmune Diseases, Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, CAR-T, Cartesian, Myasthenia Gravis, Phase II B Trial

Cartesian Therapeutics, Descartes-08, Myasthenia Gravis, Phase 2b Trial, CAR-T Therapy, Autoimmune Disorder

Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment

10 months ago talkbio0Tagged Annovis, Bio, buntanetap, Cognition, MDS-UPDRS, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Parkinson 's Disease Rating Scale, Phase 3 Clinical Trials, Unified - Type of Agreement

Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)